{"url":"https://newsforagent.com/news/2026-11-20/neurelis-chambliss-ey-entrepreneur-award","markdown_url":"https://newsforagent.com/news/2026-11-20/neurelis-chambliss-ey-entrepreneur-award.md","title":"Neurelis CEO Craig Chambliss Wins EY Entrepreneur of the Year","headline":"Neurelis CEO Craig Chambliss Named EY Entrepreneur of the Year 2026 National Overall Winner","description":"Craig Chambliss, CEO of Neurelis, was named EY's 2026 National Overall Entrepreneur of the Year, chosen from 209 regional winners across 184 companies.","section":"Business","published_at":"2026-11-20T17:36:31+00:00","modified_at":"2026-11-20T17:36:31+00:00","author":"News Desk","key_takeaways":["Craig Chambliss, CEO and co-founder of Neurelis, was named the Entrepreneur Of The Year 2026 National Overall Award winner by Ernst & Young LLP.","Chambliss was selected by an independent panel of judges from 209 regional winners representing 184 companies across the US.","Neurelis, founded in 2007, received FDA approval for its diazepam nasal spray for seizure clusters in 2020 and has since expanded the treatment to children as young as 2."],"companies":[{"name":"Neurelis","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000bxb/neurelis","website":"http://www.neurelis.com"},{"name":"EY US","is_primary":false,"profile_url":"https://akta.pro/company-profiles/02ipyts/ey-us","website":"https://www.ey.com/en_us"}],"source":{"publisher":"PR Newswire","title":"Craig Chambliss of Neurelis recognized as Entrepreneur Of The Year® 2026 National Overall Award Winner","url":"https://www.prnewswire.com/news-releases/craig-chambliss-of-neurelis-recognized-as-entrepreneur-of-the-year-2026-national-overall-award-winner-302943418.html"},"other_sources":[],"tags":["Business","Neurelis","EY US"],"body_markdown":"Craig Chambliss, CEO and co-founder of Neurelis, was named the Entrepreneur Of The Year 2026 National Overall Award winner by Ernst & Young LLP on November 20, 2026. [PR Newswire](https://www.prnewswire.com/news-releases/craig-chambliss-of-neurelis-recognized-as-entrepreneur-of-the-year-2026-national-overall-award-winner-302943418.html) reported the award, which was announced at a celebration held at the Strategic Growth Forum.\n\n## How Chambliss Won the EY Award\n\nChambliss was chosen by an independent panel of judges from 209 Entrepreneur Of The Year regional winners, representing 184 companies across the US. The judges selected winners based on entrepreneurial spirit, purpose, growth and impact.\n\n[Neurelis](https://akta.pro/company-profiles/0000bxb/neurelis) is a San Diego-based specialty pharmaceutical company that develops and commercializes intranasal therapies for neurological conditions. The company was founded in 2007, and Chambliss had seen firsthand the difference rapid treatment could make for people living with epilepsy.\n\nAfter more than a decade of navigating formulation, clinical and regulatory hurdles, Neurelis reached a milestone in 2020 with FDA approval of its diazepam nasal spray for seizure clusters. The company has since expanded the treatment's reach, including to children as young as 2 years old.\n\n\"Craig Chambliss embodies the entrepreneurial vision, purpose and impact that Entrepreneur Of The Year celebrates,\" said Anna Horndahl, EY Americas Entrepreneurship Leader and [EY US](https://akta.pro/company-profiles/02ipyts/ey-us) Assurance Partner. \"He founded Neurelis around a clear and meaningful mission: addressing unmet needs for people living with epilepsy and other neurological conditions.\"\n\nEY US also recognized 13 other Entrepreneur Of The Year 2026 National Award winners from nine companies, including Mark Barrocas of SharkNinja, Shivani Siroya of Tala and Marco Zappacosta of Thumbtack. The 209 regional winners collectively generated more than $78 billion in revenue over the past year and employ more than 155,000 people.\n\n## Neurelis Funding and Sales Figures\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Neurelis reported net sales of $295-300 million for 2025, with an EBITDA margin above 30% as of 2025. The company has raised more than $300 million in total funding historically, including a $114 million Series D round in 2021. The same records list nine funding rounds on file.\n\n## Chambliss's Path to the National Award\n\nIn June 2026, Chambliss was named the EY US Entrepreneur of the Year 2026 Pacific Southwest Award winner, recognizing his entrepreneurial leadership at the pharmaceutical company behind VALTOCO, according to BioSpace. In September 2026, Chambliss was scheduled to give a keynote at the 14th Annual Outsourcing Clinical Trials Southern California 2026 conference in San Diego on September 15-16, 2026, BioSpace reported.\n\n## What Comes After the EY Award\n\nThe national overall award winner represents the US at the World Entrepreneur Of The Year competition, EY said. The company's diazepam nasal spray was approved by the FDA in 2020 for seizure clusters.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}